Earnings History Data for Corvus Pharmaceuticals, Inc. (CRVS) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12-11-2024 | AH | CRVS | Corvus Pharmaceuticals, Inc. | 591.11 | -0.11 | -0.11 | -0.12 | Corvus Pharmaceuticals GAAP EPS of -$0.60 misses by $0.48 [11/12/2024 4:14 PM] |
8.88 | 0.19 (2.13%) |
9.56 | 0.87 (10.01%) |
1.23 - 10.00 | 1,184,729 | 910,000 | 9,085 | ||
| 06-08-2024 | AH | CRVS | Corvus Pharmaceuticals, Inc. | 187.03 | -0.07 | -0.12 | -0.14 | Corvus Pharmaceuticals GAAP EPS of -$0.07 beats by $0.05 [8/6/2024 6:07 PM] |
3.30 | 0.30 (9.88%) |
3.20 | 0.20 (6.67%) |
1.05 - 3.58 | 741,389 | 350,000 | 28,990 | ||
| 06-05-2024 | AH | CRVS | Corvus Pharmaceuticals, Inc. | 94.15 | -0.12 | -0.12 | -0.17 | Corvus Pharmaceuticals GAAP EPS of -$0.12 beats by $0.01 [5/6/2024 4:05 PM] |
1.71 | -0.20 (-10.42%) |
1.83 | -0.08 (-4.19%) |
1.05 - 4.19 | 922,126 | 260,000 | 12,808 | ||
| 19-03-2024 | AH | CRVS | Corvus Pharmaceuticals | 93.00 | -0.14 | -0.14 | 0.00 | Corvus Pharmaceuticals GAAP EPS of -$0.14 misses by $0.01 [3/19/2024 4:04 PM] |
1.85 | -0.11 (-5.61%) |
1.98 | 0.02 (1.02%) |
0.61 - 4.19 | 249,997 | 210,000 | 9,587 | ||
| 07-11-2023 | AH | CRVS | Corvus Pharmaceuticals, Inc. | 67.08 | -0.12 | -0.16 | -0.32 | Corvus Pharmaceuticals GAAP EPS of -$0.12 beats by $0.01 [11/7/2023 4:10 PM] |
1.60 | 0.02 (1.26%) |
1.66 | 0.08 (5.06%) |
0.61 - 4.19 | 560,682 | 260,000 | 16,822 | ||
| 08-08-2023 | AH | CRVS | Corvus Pharmaceuticals, Inc. | 101.52 | -0.14 | -0.14 | -0.18 | Corvus Pharmaceuticals GAAP EPS of -$0.14 in-line [8/8/2023 4:49 PM] |
2.33 | 0.19 (8.83%) |
2.21 | 0.07 (3.27%) |
0.61 - 4.19 | 374,117 | 200,000 | 3,537 | ||
| 08-05-2023 | AH | 4:05 PM ET (May 8) |
CRVS | Corvus Pharmaceuticals, Inc. | 53.55 | -0.17 | 0.00 | -0.18 | Corvus Pharmaceuticals GAAP EPS of -$0.17 misses by $0.01 [5/8/2023 4:28 PM] |
1.30 | 0.0 (0.00%) |
1.28 | -0.02 (-1.54%) |
0.61 - 1.42 | 455,769 | 230,000 | 27,244 | |
| 28-03-2023 | AH | 4:05 PM ET (Mar 28) |
CRVS | Corvus Pharmaceuticals, Inc. | 36.77 | -0.21 | 0.00 | -0.20 | Corvus Pharmaceuticals GAAP EPS of -$0.21 beats by $0.02 [3/28/2023 4:06 PM] |
0.72 | 0.07 (11.09%) |
0.66 | 0.01 (1.84%) |
0.61 - 2.11 | 579,807 | 110,000 | 19,366 | |
| 03-11-2022 | AH | 4:05 PM ET (Nov 3) |
CRVS | Corvus Pharmaceuticals, Inc. | 40.12 | -0.32 | 0.00 | -0.24 | Corvus Pharmaceuticals GAAP EPS of -$0.32 misses by $0.16 [11/3/2022 4:32 PM] |
0.8350 | -0.03 (-3.36%) |
0.87 | 0.01 (0.69%) |
0.69 - 5.25 | 100,540 | 130,000 | 500 | |
|
||||||||||||||||||
| 08-08-2022 | AH | 4:05 PM ET (Aug 8) |
CRVS | Corvus Pharmaceuticals, Inc. | 44.92 | -0.18 | -0.19 | -0.28 | Corvus Pharmaceuticals GAAP EPS of -$0.18 in-line [8/8/2022 4:22 PM] |
0.8797 | -0.08 (-8.36%) |
0.92 | -0.04 (-4.69%) |
0.75 - 9.54 | 743,351 | 350,000 | 6,345 | |
| 10-03-2022 | AH | 4:05 PM ET (Mar 10) |
CRVS | Corvus Pharmaceuticals, Inc. | 71.22 | -0.20 | -0.20 | -0.35 | Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01 [3/10/2022 4:14 PM] |
1.51 | -0.08 (-4.86%) |
1.60 | 0.01 (0.63%) |
1.50 - 9.54 | 217,883 | 150,000 | 1,862 | |
| 01-11-2021 | AH | 4:05 PM ET (Nov 1) |
CRVS | Corvus Pharmaceuticals | 196.00 | -0.24 | -0.30 | 0.00 | Corvus Pharmaceuticals EPS misses by $0.03 [11/1/2021 5:14 PM] |
4.96 | 0.13 (2.69%) |
4.80 | -0.03 (-0.62%) |
1.86 - 9.54 | 1,087,011 | 680,000 | 23,715 | |
|
||||||||||||||||||
| 02-08-2021 | AH | CRVS | Corvus Pharmaceuticals, Inc. | 83.00 | -0.28 | -0.32 | 0.00 | Corvus Pharmaceuticals EPS in-line [8/2/2021 4:40 PM] |
2.10 | -0.04 (-1.87%) |
2.14 | 0.0 (0.00%) |
2.04 - 5.74 | 278,918 | 310,000 | 101 | ||
| 29-04-2021 | AH | After the close (Apr 29) |
CRVS | Corvus Pharmaceuticals, Inc. | 107.65 | -0.34 | -0.33 | -0.44 | Corvus Pharmaceuticals EPS misses by $0.04 [4/29/2021 4:52 PM] |
2.81 | -0.01 (-0.35%) |
2.90 | 0.08 (2.84%) |
2.12 - 6.88 | 96,133 | 180,000 | 703 | |
| 25-03-2021 | PM | CRVS | Corvus Pharmaceuticals, Inc. | 124.89 | -0.35 | -0.32 | -0.38 | Corvus Pharmaceuticals EPS beats by $1.16 [3/25/2021 8:59 AM] |
3.10 | 0.24 (8.39%) |
2.86 | 0.0 (0.00%) |
1.91 - 6.88 | 471,363 | 570,000 | 16,472 | ||
| 29-10-2020 | AH | CRVS | Corvus Pharmaceuticals, Inc. | 115.00 | -0.33 | -0.25 | 0.00 | Corvus Pharmaceuticals EPS misses by $0.06 [10/29/2020 4:58 PM] |
3.91 | -0.08 (-2.00%) |
3.96 | -0.03 (-0.75%) |
1.01 - 6.88 | 143,437 | 164,799 | 301 | ||
|
|
||||||||||||||||||